



PERSONAL INFORMATION

Name
e-mail
address PEC

GIUSEPPA PISTRITTO
giuseppa.pistritto@unicamillus.org
pistritto.giuseppa@omceoromapec.it

WORKING EXPERIENCE AIFA

• August 2023 - August 2024

Technical_scientific support to the process of Post Authorization Procedures Office

• February 2021 - February 2023
• Employer name
• Type of employment
• Main responsibilities

Head of Post Authorization Procedures Office

Italian Medicines Agency - AIFA
Head Medical Office
Management of procedures relating to applications for variations to the marketing authorisation and renewal of national, decentralised and mutual recognition procedures

• February 2018 - February 2021
• Employer name
• Type of employment
• Main responsibilities

Head Unit of Centralized Procedure Office

Italian Medicines Agency - AIFA
Head Medical Office
Coordinator of technical_scientific support for Italian activities at the Committee for Medicine products for Human Use (CHMP) and its Working parties, the Paediatric Committee (PDCO) and the Committee for Advanced Therapies (CAT); Management of regulatory aspects in the national authorization process for drugs approved by a centralised procedure; Technical - scientific support to the process of defining the repayable of medicines approved by a centralised procedure

• February 2021 - July 2021
• Employer name
• Type of employment
• Main responsibilities

Head Unit of Centralized procedure office *ad interim*

Italian Medicines Agency - AIFA
Head Medical Office
same as above

• September 2017

Head Medical Office
Italian Medicines Agency - AIFA

• 2013 - 2016
• Employer name
• Type of employment
• Main responsibilities

Clinical medical *Assessor* - Centralized procedure office
Italian Medicines Agency - AIFA
Commitment from University of Tor Vergata - Faculty of Medicine and Surgery
Evaluation of dossiers for safety/efficacy aspects for drugs approved through the centralised procedure

SCIENTIFIC COMMITTEES EMA

- June 2019 - August 2020
- Employer name
- Type of employment

- April 2018 - July 2019
- Employer name
- Type of employment

- 2013 - present

IT CHMP “*alternate*” member - EMA

EMA - European Medicine Agency - Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Italian delegate on the Committee for the Evaluation of Medicinal Products for Human Use (CHMP)

Observer CAT - EMA

EMA - European Medicine Agency - 30 Churchill Place, Londra E14 5EU, Regno Unito Londra, UK

Final opinion for assessing the quality, safety and efficacy of advanced therapy medicinal products (ATMP)

Clinical expert European network (Experts Database EMA)

<https://www.ema.europa.eu/en/about-us/how-we-work/european-medicines-regulatory-network/european-experts/>

ACADEMIC POSITION

- **2006 - 2017**
- Employer name
- Type of employment
- Main responsibilities

- **1990 - 2006**
- Employer name
- Type of employment
- Main responsibilities

- **1999 - 2000**
- Employer name
- Main responsibilities

- **2000 - 2002**
- Employer name
- Main responsibilities

Aggregate Professor of Pharmacology

“Dept “Systems Medicine” University of Rome Tor Vergata Medical School - (Italy)
Tenured Professor

Research activity and Pharmacology Teaching

Adjunct Researcher - Pharmacology

Dept “Neuroscience”, Tor Vergata University - Roma

Tenured Researcher

Research activity and Pharmacology Teaching

Fellowship Programme NATO - CNR

“Kimmel Cancer Institute”, Thomas Jefferson University, (Philadelphia, USA)

Biomolecular research applied to cell differentiation and apoptosis

Scientific Researcher - PhD Fellow

“Kimmel Cancer Institute”, Thomas Jefferson University, (Philadelphia, USA)

Biomolecular research applied to cell differentiation and apoptosis

TEACHING ACTIVITY

Lecturer at the II level Master 2022/2023: “Preclinical and clinical drug development: technical-scientific, regulatory and ethical aspects” Catholic University of Sacred Heart, ROMA

Lecturer at the School of Specialisation in ‘Hospital Pharmacy’, Catholic University of the Sacred Heart, ROMA

<https://docenti.unicatt.it/ppd2/en/docenti/94483/giuseppa-pistritto/didattica>

Professor of Pharmacology:

- University of Tor Vergata - Medical School
- Degree in Medicine and Surgery - Degree in Nursing
- Degree in Cardiovascular Physiopathology and Cardiovascular Perfusion
- Degree in Radiologic Technology
- Residency in Orthopedics and Trauma
- Degree in Medicine and Surgery and in Dentistry and Dental Prosthesis “Our Lady of the Good Counsel” - Tirana - Albany
- Degree in Dental Hygiene Technology
- Master in “Applied Physiotherapy in Manual Therapy”

UNIVERSITY ACTIVITIES

Tutor and supervisor of Ph. D. students

- Member of the Degree Commissions for ‘Medicine and Surgery’ and ‘Dentistry’.
- Member of Degree Commissions for the degree course in ‘CTF’, Universities ‘Tor Vergata’ and “La Sapienza” - Rome
- Supervisor for ‘Master’s thesis in Neuroscience’ Tor Vergata University
- National research projects (PRIN, University research funds, Region funds Calabria)
- Member of international projects (AIRC, FIRB, CNR-NATO)
- Reviewer for National and International Research Projects (AIRC, FIRB, PRIN)

Field research

- Neural stem cell differentiation and potential therapeutic application in response to neuronal damage
- Biomedical engineering applied to regenerative cell therapies
- Apoptosis and neuronal differentiation
- Apoptosis and resistance to chemotherapy Involvement of p53
- Characterisation and pharmacological modulation of the expression of mediators of inflammation in vivo and in vitro (prostaglandins, nitric oxide, inflammatory interleukins)

Research bibliometric indicators

58 International publications (PubMed)

Web of Science Researcher ID: HMW-0205-2023

H Index ISI Web of Science (WOS): 23 Citations ISI WoS: 2993

4 book chapters

ORCID ID:

<https://orcid.org/0000-0002-3465-3566>

EDUCATION AND

TRAINING

• 2017

- Name of the Institution and type
- Main topics of training
- Title acquired

• 1992

• 1992

(SNA) National School of Administration - 26° cycle of training activities for new public managers Rome
SNA - Presidency of the Council of Ministers
Professional training for public Administration Management
Qualification for Public Administration Management

M.D. Degree: (cum laude) - Università di Catania

- Physician State Board exam, approved
- Iscrizione all'Ordine dei medici della provincia di Roma (n. 0000044742)

PERSONAL CAPABILITIES AND COMPETENCIES

• MOTHER TONGUE

OTHER TONGUES

- Reading
- Writing
- Speaking

COMPETENCIES AND OTHER RELATIONAL CAPABILITIES

ITALIAN

ENGLISH

EXCELLENT
EXCELLENT
EXCELLENT

- Excellent interpersonal skills gained both in the working environment of AIFA and in university environment with teaching experience.
- Excellent interpersonal skills in the international sphere gained both for the years spent as a scientist in the USA and as an Italian representative member of the CAT and the CHMP.

ORGANIZATIONAL CAPABILITIES

- Autonomy in work management, ability to set priorities and assumption of responsibility acquired through various professional experiences
- Organisational and analytical skills, problem-solving skills, teamwork team
- Ability to work in stressful situations acquired through the management of work schedules of AIFA and EMA international procedures. Management of 'rolling reviews' for the approval of anti-Covid 19 vaccines and antibodies monoclonal antibodies both in EMA and in Italy (temporary distribution authorisation, DM 6 February, 2021)

TECHNICAL SKILLS

- Excellent knowledge of search engines and websites useful for acquiring scientific information.
- Good knowledge of IT tools, with particular reference to the Windows environment and to the Office package and AIFA applications.
- Good knowledge of Internet browsing, use of e-mail.

SPECIAL ACTIVITY IN AIFA

- Head of task force for review procedure of medicinal products based on ranitidine (Referral EMA art. 31).
- Head of 'Nitrosamines' Working Group (Referral EMA art. 5.3).
- Member 2021 of Joint Committee for Equal Opportunity (CUG) of Aifa.
- Member of Aifa scientific secretariat for COVID-19 vaccine Surveillance.
- Coordinator working group 'Monoclonal antibodies' authorised for emergency use for emergency use for pandemic Covid-19 (temporary distribution authorisation, DM 6 February, 2021).
- Coordination of EMA - CHMP procedures (rolling review) for the approval of COVID-19 vaccines and monoclonal antibodies in EMA.
- Member of examining board in Aifa competitions for medical executive (residency in haematology) - Det DG 175 / 2022 and for medical executive (Residency in Internal Medicine or Anaesthesia and Resuscitation) - Det DG 547/2021.

OTHER INFORMATIONS

• Editorial activity

- Editorial Board Member: Frontiers of pharmacology.
- Reviewer of scientific papers for international journals (JPET; PLOS ONE; Oncotarget; Journal of experimental & clinical cancer research; Stem cell research; Expert Opinion on Therapeutic Targets; FEBS Letters; Frontiers in Pharmacology)

• Memberships

- Società Italiana di Farmacologia (SIF)
- International Society for Neuroscience SfN)
- International Society for Cellular Therapy (ISCT)
- International Society for Stem Cell Research (ISSCR)

• Patents

National patent for Italy: N. 102013902200191"

SELECTED PUBLICATIONS

Author of numerous international publications (Pubmed) in journals indexed in Journal Citation Reports (ISI)

- Barillari G., Albonici L., Incerpi S., Bogetto L., Pistritto G., Volpi A., Ensoli B. and Mannari V.: Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing alpha5beta1 integrin expression and function. *Atherosclerosis*, 2001, 154 :377-85
- Pistritto G., Jost M., Srinivasula S.M., Baffa R., Poyet J.L., Kari C., Lazebnik Y., Rodeck U. and Alnemri E.S.: Expression and transcriptional regulation of caspase-14 in simple and complex epithelia. *Cell Death Differ*, 2002, 9: 995-1006
- Sauter E.R., Yeo U-C., von Stemm A., Zhu W., Samuel Litwin S., Tichansky D.S., Pistritto G., Nesbit M., Pinkel D., Herlyn M., Bastian B.C.: Cyclin D1 is a candidate oncogene in cutaneous melanoma. *Cancer Res*, 2002, 62: 3200-6
- Sciulli MG., Seta F., Tacconelli S., Capone M.L., Ricciotti E., Pistritto G., Patrignani P.: Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. *Br J Pharmacol*, 2003, 138: 634-41
- Pistritto G., R Puca, L Nardinocchi, A Sacchi and D'Orazi G: HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway. *Cell Death Differ*, 2007, 14: 1837-1839
- Puca R., Nardinocchi L., Pistritto G., D' Orazi G.: Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. *Gynecol Oncol*. 2008, 109: 403-410
- Pistritto G., Papacleovoulou G, Ragone G, Di Cesare S, Papaleo V, Mason JJ, Barbaccia ML.: Differentiation-dependent progesterone synthesis and metabolism in NT2-N human neurons. *Exp Neurol*. 2009, 217: 302-11
- Ricciotti E, Dovizio M, Di Francesco L, Anzellotti P, Salvatore T, Di Francesco A, Sciulli MG, Pistritto G, Monopoli A, Patrignani P. NCX 4040, a nitric oxide-donating Aspirin, Exerts Anti- Inflammatory Effects through Inhibition of IkappaB-alpha degradation in human monocytes. *J Immunol*. 2010, 184: 2140-7
- Bortolato M, Devoto P, Roncada P, Frau R, Flore G, Saba P, Pistritto G, Soggiu A, Pisanu S, Zappala A, Ristaldi MS, Tattoli M, Cuomo V, Marrosu F, Barbaccia ML. Isolation rearing-induced reduction of brain 5 α -reductase expression: relevance to dopaminergic impairments. *Neuropharmacol*. 2011, 60:1301-8
- Pistritto G, Papaleo V, Sanchez P, Ceci C, Barbaccia ML. Divergent modulation of neuronal differentiation by caspase-2 and -9. *PLoS ONE*, 2012, 7: e36002
- Garufi A, Pistritto G, Ceci C, Di Renzo L, Santarelli R, Faggioni A, Cirone M, D'Orazi G. Targeting HIF-1-induced COX-2/PGE2 pathway upregulated in HIPK2 knockdown cancer cells: correlation with dendritic cell maturation. *PLoS ONE*, 2012, ;7: e48342
- Garufi A, Ricci A, Trisciuglio D, Iorio E, Carpinelli G, Pistritto G, Cirone M, D'Orazi G. Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapy. *Cell Death Dis*. 2013 4: e639
- Ceci C, Barbaccia ML, Pistritto G. A not cytotoxic nickel concentration alters the expression of neuronal differentiation markers in NT2 cells. *Neurotoxicology*. 2015, 47: 47-53
- Pistritto G, Trisciuglio D, Ceci C, Garufi A, D'Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. *Aging (Albany NY)*. 2016 Apr;8: 603-19

- Garufi A, Pistritto G, Cirone M, D’Orazi G. Reactivation of mutant p53 bycapsaicin, the major constituent of peppers. *J Exp Clin Cancer Res.* 2016; 35: 136
- Baldari S, Garufi A, Granato M, Cuomo L, Pistritto G, Cirone M, D’Orazi G. Hyperglycemia triggers HIPK2 protein degradation. *Oncotarget.* 2017; 8: 1190-1203
- Cacciotti I, Ceci C, Bianco A, Pistritto G. Neuro-differentiated Ntera cancer stem cells encapsulated in alginate beads: First evidence of biological functionality. *Mat Sci Eng c.* 2017; 81: 32-38
- Garufi A, Pistritto G, Baldari S, Toietta G, Cirone M, D’Orazi G. p53-Dependent PUMA to DRAM antagonistic interplay as a key molecular switch in cell-fate decision in normal/high glucose conditions. *J Exp Clin Cancer Res.* 2017; 11; 36: 126
- Marangi M, Pistritto G. Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique. *Front Pharmacol.* 2018; 9:396
- Marangi M, Ivanovic J, Pistritto G. The Horizon Scanning System at The Italian Medicines Agency. *Drug Discov Today.* 2019 24:1268-1280
- Garufi A, Traversi G, Gilardini Montani MS, D’Orazi V, Pistritto G, Cirone M, D’Orazi G. Reduced chemotherapeutic sensitivity in high glucose condition: implication of antioxidant response. *Oncotarget.* 2019;10: 4691-4702
- Garufi A, Baldari S, Pettinari R, Gilardini Montani MS, D’Orazi V, Pistritto G, Crispini A, Giorno E, Toietta G, Marchetti F, Cirone M, D’Orazi G. A ruthenium (II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status. *J Exp Clin Cancer Res.* 2020: 39:122
- Garufi A, Giorno E, Gilardini Montani MS, Pistritto G, Crispini A, Cirone M, D’Orazi G. P62/SQSTM1/Keap1/NRF2 Axis Reduces Cancer Cells Death-Sensitivity in Response to Zn (II)-Curcumin Complex. *Biomolecules.* 2021; 11: 348.
- Garufi A, Pistritto G, D’Orazi V, Cirone M, D’Orazi G. The Impact of NRF2 Inhibition on Drug-Induced Colon Cancer Cell Death and p53 Activity: A Pilot Study. *Biomolecules.* 2022; 12: 461
- Garufi A, Pistritto G, D’Orazi G. HIPK2 as a Novel Regulator of Fibrosis. *Cancers.* 2023; 15: 1059
- Garufi A, D’Orazi V, Pistritto G, Cirone M, D’Orazi G. HIPK2 in Angiogenesis: A Promising Biomarker in Cancer Progression and in Angiogenic Diseases. *Cancers.* 2023; 15: 1566
- Garufi A, D’Orazi V, Pistritto G, Cirone M, D’Orazi G. The Sweet Side of HIPK2. *Cancers.* 2023;15: 2678

BOOK CHAPTERS

- Pistritto G.: Terapie avanzate: le speranze del domani. In: *Appunti di Farmacologia dei Sistemi.* Trabucchi M., & Barbaccia M.L. (eds): ROMA: UNIVERSITALIA, 2014. pp.181-201
- Pistritto G: Compliance o aderenza: uno strumento essenziale per l’efficacia terapeutica. In: *I farmaci e le sfide di una medicina a misura di paziente.* Trabucchi M., & Barbaccia M.L. (eds): ROMA: UNIVERSITALIA, 2015. pp. 79-98
- Pistritto G., Ventura L., Mores N., Lacal P.M., and D’Onofrio C.: Regulation of PDGF-B and PDGF receptor expression in the pathogenesis of Kaposi’s sarcoma in AIDS. In: *Antibiot. Chemother. Advanced Technologies in Research Diagnosis and Treatment of AIDS and in Oncology.* Giraldo G., Salvatore M., Chieco-Bianchi L., Beth-Giraldo E.(eds): Basel, Karger, 1994, vol. 46, 73-87

